Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · IEX Real-Time Price · USD
6.39
+0.05 (0.79%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Fennec Pharmaceuticals Revenue
Fennec Pharmaceuticals had revenue of $44.95M in the twelve months ending March 31, 2024, with 1,299.50% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $25.38M with 1,413.24% year-over-year growth. In the year 2023, Fennec Pharmaceuticals had annual revenue of $21.25M with 1,284.50% growth.
Revenue (ttm)
$44.95M
Revenue Growth
+1,299.50%
P/S Ratio
3.88
Revenue / Employee
$1,550,069
Employees
29
Market Cap
174.59M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 21.25M | 19.72M | 1,284.50% |
Dec 31, 2022 | 1.54M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 170.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Jun 30, 2004 | 0 | - | - |
Jun 30, 2003 | 0 | - | - |
Jun 30, 2002 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accuray | 430.55M |
Puma Biotechnology | 226.63M |
Rigel Pharmaceuticals | 120.35M |
Innate Pharma | 68.49M |
INmune Bio | 131.00K |
FENC News
- 21 days ago - Fennec Pharmaceuticals Announces Management Change - GlobeNewsWire
- 26 days ago - Fennec Announces Results of Annual Meeting - GlobeNewsWire
- 2 months ago - Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 - GlobeNewsWire
- 4 months ago - Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 - GlobeNewsWire
- 4 months ago - Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - GlobeNewsWire
- 5 months ago - Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results - GlobeNewsWire